**ASX / Media Release**

# AKI Burden of Illness Data Presented at Premier® Breakthroughs Conference

**June 21, 2019 - Minnesota, United States and Melbourne, Australia –** Osprey Medical (ASX: OSP) today announces that Dr Anand Prasad, M.D., Director of the Cardiac Catheterization Laboratory at University Health System and Associate Professor of Medicine at UT Health Science Centre at San Antonio, Texas presented the Acute Kidney Injury (AKI) Burden of Illness Study[1] at the Premier Breakthroughs 2019 Conference and Exhibition in Nashville, Tennessee on behalf of the study investigators.

Premier Inc. (NASDAQ:PINC) is a leading healthcare improvement company that unites more than 4,000 hospitals and 165,000 other healthcare providers to transform healthcare. Premier's annual Breakthroughs Conference and Exhibition, an exclusive member event, convenes healthcare thought leaders and peers across the care continuum to drive knowledge sharing and collaboration. The Conference attracts approximately 5,000 delegates from across the Premier member hospitals. As recently announced, Osprey is working with Premier to offer members of its QUEST® quality improvement collaborative hospital-level burden of illness reports on AKI and is a recipient of a Technology Breakthroughs Award.

These hospital-level reports originate from The AKI Burden of Illness Study which was published at the American College of Cardiology (ACC) Annual Scientific Conference in March 2019, showing AKI incidence, risk factors, and costs among 2.8 million US patients across 749 hospitals undergoing Percutaneous Coronary Procedures from the Premier Healthcare Database. Osprey has previously commented on this study, which demonstrated a significant cost burden of $1.7 billion to Premier hospitals, a very significant increase in the rate of AKI from 18% in 2012 to 28% in 2017 and a 61% higher rate of death in patients who experienced an AKI event.

Dr. Anand Prasad commented "the burden of illness analysis reflects the growing rate of AKI, the poor clinical outcomes for patients and the costs to hospitals in the US. Multidisciplinary evidence-based approaches consistent with Cardiology professional society guidelines including screening for risk, hydration and reduced contrast volume are needed to address this rising problem of AKI."

Osprey Medical's President and CEO, Mike McCormick, said "Following on from the publication at the American College of Cardiology Annual Scientific Conference in March 2019, the AKI Burden of Illness study continues to attract significant interest at influential scientific meetings with a major podium presence. We believe the US$1.7 billion in costs associated with AKIs at Premier hospitals and markedly higher AKI incidence rates following coronary interventions over the five years observed, will drive continued growth in the utilisation of our innovative DyeVert™ platform as the only FDA cleared devices proven to reduce contrast dye volume delivered to patients without impacting image quality."

**– ENDS –**

[1] Prasad, A. *et al.* 2019. Acute Kidney Injury Incidence, Risk Factors, and Costs Among U.S. Patients Undergoing Percutaneous Coronary Procedures. American College of Cardiology Annual Meeting. Poster Presentation.

**Contact details:**


| Media | Investors | Company |
|---|---|---|
| Kyahn Williamson | Dr Thomas Duthy | Doug Schoenberg |
| WE Buchan | Investor Relations | VP of Marketing |
| M: (61) 401 018 828 | M: (61) 402 493 727 | T: (952) 955 8230 |
| kwilliamson@we-buchan.com | tduthy@ospreymed.com | dschoenberg@ospreymed.com |


**About Osprey Medical (ASX: OSP)**

Osprey Medical's vision is to make heart imaging procedures safer for patients with poor kidney function. The amount of dye (contrast) used during angiographic imaging procedures increases the patient's risk for dye-related kidney damage known as Contrast-Induced Acute Kidney Injury (CI-AKI). The Company's core technologies originated from research conducted by Dr David Kaye at Melbourne's Baker Institute. Its proprietary dye reduction and monitoring technologies are designed to help physicians minimize dye usage and monitor the dose of dye real time throughout the procedure. The Company's DyeVert™ System reduces contrast while maintaining image quality in a self-adjusting easy-to-use design that monitors dye usage. Osprey Medical's Board and Management are comprised of experienced and successful personnel with established track records covering medical device development, regulatory approvals, sales and marketing, and mergers-acquisitions. Osprey Medical's advisory board comprises world-recognised experts in heart and kidney diseases.

**Forward-Looking Statements**

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions, and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to commercialize our products including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position. Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Osprey does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Osprey may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

**Foreign Ownership Restriction**

Osprey's CHESS Depositary Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities Act) for offers or sales which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. The holders of Osprey's CDIs are unable to sell the CDIs into the US or to a US person unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. Hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.